Publications by authors named "Geeta Devgan"

Claim this Profile
P
Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
Sigrid V Carlsson, Pedro C Barata, Alan H Bryce, Daniel J George, Silke Gillessen, Geeta Devgan

JCO Oncol Pract· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers.
Jennifer Lloyd, Nazy Zomorodian, Geeta Devgan, Julia Batten

Clin J Oncol Nurs· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.
Rana R McKay, Alicia K Morgans, Neal D Shore, Curtis Dunshee, Geeta Devgan

Cancer Treat Rev· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Oncologists' Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study.
Shilpa Gupta, Halley Costantino, Chiemeka Ike, Shaloo Gupta, Abhijeet Bhanegaonkar, Geeta Devgan

Oncologist· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.
Maria Lapuente, Dawn Conway, Laura S Wood, Kiran Kehoe, Andrea Carroll Bullock, Geeta Devgan

Clin J Oncol Nurs· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses.
Laura S Wood, Dawn Conway, Maria Lapuente, George Salvador, Sheila Fernandez Gomez, Geeta Devgan

J Infus Nurs· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
Saby George, Elizabeth J Bell, Ying Zheng, Ruth Kim, John White, Geeta Devgan

Oncologist· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
Petros Grivas, Neeraj Agarwal, Sumanta Pal, Arash Rezazadeh Kalebasty, Srikala S Sridhar, Geeta Devgan

Cancer Treat Rev· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
Mollie Reed, Aimee-Lauren S Rosales, Marc D Chioda, Lindsey Parker, Geeta Devgan

Adv Ther· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dose modifications on the safety and efficacy of dacomitinib for mutation-positive non-small-cell lung cancer.
Jesús Corral, Tony S Mok, Kazuhiko Nakagawa, Rafael Rosell, Ki Hyeong Lee, Geeta Devgan

Future Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.
Eric Pujade-Lauraine, Keiichi Fujiwara, Samuel S Dychter, Geeta Devgan, Bradley J Monk

Future Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.
Nathalie Bardy-Bouxin, Ewa Matczak, Geeta Devgan, Mabel Woloj, Mark Shapiro

Biologics· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initiation of the TORC1-regulated G0 program requires Igo1/2, which license specific mRNAs to evade degradation via the 5'-3' mRNA decay pathway.
Nicolas Talarek, Elisabetta Cameroni, Malika Jaquenoud, Xuan Luo, Séverine Bontron, Geeta Devgan

Mol Cell· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.
Kenneth Leslie, Cynthia Lang, Geeta Devgan, Janeen Azare, Marjan Berishaj

Cancer Res· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global analysis of protein phosphorylation in yeast.
Jason Ptacek, Geeta Devgan, Gregory Michaud, Heng Zhu, Xiaowei Zhu

Nature· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substrate specificity analysis of protein kinase complex Dbf2-Mob1 by peptide library and proteome array screening.
Angie S Mah, Andrew E H Elia, Geeta Devgan, Jason Ptacek, Mike Schutkowski

BMC Biochem· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global analysis of protein function using protein microarrays.
Michael G Smith, Ghil Jona, Jason Ptacek, Geeta Devgan, Heng Zhu

Mech Ageing Dev· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis